Painful Diabetic Neuropathy Treatment: A Guideline Topline
Painful diabetic neuropathy (PDN) affects more than 16% of patients with diabetes and is the most common form of peripheral neuropathy.
The American Academy of Neurology recently issued a guideline on oral and topical treatments for PDN published in the journal Neurology, which updated its 2011 guidance. Authors searched the literature from January 2008 to April 2020 using a structured review process to classify the evidence and develop practice recommendations. In the slides below, find a concise summary of the guideline.
Painful Diabetic Neuropathy (PDN) Treatment Classes: Gabapentinoids, SNRIs, TCAs, sodium channel blockers, SNRI/opioid dual mechanism agents.
Gabapentinoids, SNRIs for PDN
TCAs, Sodium Channel Blockers for PDN
SNRI/Opioid Dual Mechanism Agents for PDN
Topical Analgesics for PDN
Few Studies Compare Medications for PDN
Head-to-head Studies of PDN Treatments are Limited
American Academy of Neurology Guideline Recommendations for PDN
AAN: Consider Comorbidities, AEs when Choosing PDN Treatment
AAN: Three-month Trial for Initial PDN Treatment
AAN: Some Nonpharmacologic Therapies May Benefit PDN
AAN: Recommends Strongly Against Opioids for PDN
